Tg Therapeuticscmn (TGTX) 6.53 $TGTX TG Therape
Post# of 273258
Posted On: 09/02/2016 9:04:45 PM
Tg Therapeuticscmn (TGTX) 6.53 $TGTX
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
GlobeNewswire - Wed Aug 31, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that data from a Phase 1b open label study of TG-1101 (ublituximab) in acute relapses of neuromyelitis optica spectrum disorder (NMOSD), has been selected for presentation at the upcoming 32 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held from September 14 - 17, 2016, at the ExCel London, in London, United Kingdom. Details for the poster presentation are as follows:
TGTX: 6.53 (+0.02)
TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
GlobeNewswire - Fri Aug 26, 7:00AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TG-1101 (ublituximab) the Company's novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). There are currently no FDA approved treatments for NMO or NMOSD.
TGTX: 6.53 (+0.02)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.73 (+0.45), TGTX: 6.53 (+0.02)
TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
GlobeNewswire - Wed Aug 24, 8:25AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's oral, next generation PI3K Delta inhibitor, TGR-1202, for the treatment of patients with chronic lymphocytic leukemia (CLL). TGR-1202 is currently being evaluated in the UNITY-CLL Phase 3 Trial for patients with both frontline and previously treated CLL.
TGTX: 6.53 (+0.02)
PrEP Biopharm Limited announces new CFO, Mike McGuinness, and new Head of CMC, Anna Slater
PR Newswire Europe - Thu Aug 11, 6:01AM CDT
PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced today that effective immediately Mike McGuinness has joined the company as Chief Financial Officer and Anna Slater has joined as Head of Chemistry, Manufacturing and Controls.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon Aug 08, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 2016 and recent company developments.
TGTX: 6.53 (+0.02)
Investor Calendar Invites You to the TG Therapeutics, Inc. Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 8, 2016
ACCESSWIRE - Fri Aug 05, 3:10PM CDT
NEW YORK, NY / ACCESSWIRE / August 5, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the second quarter 2016, to be held Monday, August 8, 2016 at 8:30 AM Eastern Time.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu Aug 04, 3:17PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, August 8, 2016 at 8:30am ET to discuss results for the second quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 6.53 (+0.02)
Chronic Lymphocytic Leukemia Market to Grow at 19% CAGR to 2020
PR Newswire Europe - Thu Jun 23, 7:30AM CDT
PUNE, India, June 23, 2016 /PRNewswire/ --
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
GlobeNewswire - Fri Jun 10, 8:15AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, the Company's once daily PI3K delta inhibitor, both alone and in combination with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, as well as data presented for the first time from a Phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed/refractory CLL or MCL.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 09, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York, NY. The presentation is scheduled to take place on Friday June 10, 2016 at 10:00am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
GlobeNewswire - Tue Jun 07, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's orally available PI3K delta inhibitor, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL).
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Mon Jun 06, 8:00AM CDT
High response rates observed across CLL, DLBCL & indolent NHL
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Thu Jun 02, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.53 (+0.02)
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
GlobeNewswire - Fri May 27, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ("Jubilant"
, an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. ("Checkpoint", a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
GlobeNewswire - Fri May 20, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 21 European Hematology Association (EHA) Annual Congress, to be held from June 9 - 12, 2016 in Copenhagen, Denmark.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Wed May 18, 4:15PM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Tue May 10, 3:00PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2016 and recent company developments.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon May 09, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 10, 2016 at 4:30pm ET to discuss results for the first quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
GlobeNewswire - Wed Aug 31, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that data from a Phase 1b open label study of TG-1101 (ublituximab) in acute relapses of neuromyelitis optica spectrum disorder (NMOSD), has been selected for presentation at the upcoming 32 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held from September 14 - 17, 2016, at the ExCel London, in London, United Kingdom. Details for the poster presentation are as follows:
TGTX: 6.53 (+0.02)
TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
GlobeNewswire - Fri Aug 26, 7:00AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TG-1101 (ublituximab) the Company's novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). There are currently no FDA approved treatments for NMO or NMOSD.
TGTX: 6.53 (+0.02)
TG Therapeutics (TGTX) Catches Eye: Stock Jumps 9.2%
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:00AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
GWPH: 82.73 (+0.45), TGTX: 6.53 (+0.02)
TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
GlobeNewswire - Wed Aug 24, 8:25AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's oral, next generation PI3K Delta inhibitor, TGR-1202, for the treatment of patients with chronic lymphocytic leukemia (CLL). TGR-1202 is currently being evaluated in the UNITY-CLL Phase 3 Trial for patients with both frontline and previously treated CLL.
TGTX: 6.53 (+0.02)
PrEP Biopharm Limited announces new CFO, Mike McGuinness, and new Head of CMC, Anna Slater
PR Newswire Europe - Thu Aug 11, 6:01AM CDT
PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced today that effective immediately Mike McGuinness has joined the company as Chief Financial Officer and Anna Slater has joined as Head of Chemistry, Manufacturing and Controls.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon Aug 08, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 2016 and recent company developments.
TGTX: 6.53 (+0.02)
Investor Calendar Invites You to the TG Therapeutics, Inc. Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 8, 2016
ACCESSWIRE - Fri Aug 05, 3:10PM CDT
NEW YORK, NY / ACCESSWIRE / August 5, 2016 / TG Therapeutics, Inc. (NASDAQ: TGTX) will host a live conference call and webcast to discuss the results of the second quarter 2016, to be held Monday, August 8, 2016 at 8:30 AM Eastern Time.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu Aug 04, 3:17PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Monday, August 8, 2016 at 8:30am ET to discuss results for the second quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 6.53 (+0.02)
Chronic Lymphocytic Leukemia Market to Grow at 19% CAGR to 2020
PR Newswire Europe - Thu Jun 23, 7:30AM CDT
PUNE, India, June 23, 2016 /PRNewswire/ --
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
GlobeNewswire - Fri Jun 10, 8:15AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced data presented during the 21 Annual Congress of the European Hematology Association (EHA) being held in Copenhagen, Denmark. These presentations include long term follow-up data of TGR-1202, the Company's once daily PI3K delta inhibitor, both alone and in combination with TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, as well as data presented for the first time from a Phase I/Ib study of TGR-1202 in combination with ibrutinib in patients with relapsed/refractory CLL or MCL.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 09, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference being held at the Grand Hyatt in New York, NY. The presentation is scheduled to take place on Friday June 10, 2016 at 10:00am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
GlobeNewswire - Tue Jun 07, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's orally available PI3K delta inhibitor, as well as TGR-1202 alone, in patients with previously treated Diffuse Large B-Cell Lymphoma (DLBCL).
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Mon Jun 06, 8:00AM CDT
High response rates observed across CLL, DLBCL & indolent NHL
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Thu Jun 02, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.53 (+0.02)
TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
GlobeNewswire - Fri May 27, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that as part of a broader agreement with Jubilant Biosys ("Jubilant"
, an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, Inc. ("Checkpoint", a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
GlobeNewswire - Fri May 20, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 21 European Hematology Association (EHA) Annual Congress, to be held from June 9 - 12, 2016 in Copenhagen, Denmark.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
GlobeNewswire - Wed May 18, 4:15PM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that updated data has been selected for presentation at the upcoming 52 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 3 - 7, 2016, at McCormick Place in Chicago, Illinois.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Tue May 10, 3:00PM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the first quarter ended March 31, 2016 and recent company developments.
TGTX: 6.53 (+0.02)
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Mon May 09, 6:30AM CDT
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 10, 2016 at 4:30pm ET to discuss results for the first quarter of 2016 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 6.53 (+0.02)
(0)
(0)Scroll down for more posts ▼